



PMCF Survey on the Performance and Usability of 2334 matrix® implants after 15 months

Study executed by renowned and independent AMR-CRO Clinical Research Organisation.



Study Set-up:

matrix® is a dental implant which is CE and FDA approved for fully digitally single and multi-unit restorations directly on the implant without the use of an abutment. TRI® obtained CE marking in October 2020. This survey was conducted in December 2021. This survey aimed to document the clinical performance of matrix® among the TRI® lead user group after 15 months since first implants installed.



Prof. Ronald Jung



Prof Tomas Linkevičius



Dr. Ramón



Dr. Andrea & Gómez Meda Alessandro Agnini



Dr. Alecsandru lonescu



Peev




Dr Joel Teles



Prof. Constantin von See



Dr Marco **Zeltner**



Total number of 2334 matrix[®] implants placed.



6/10 participants could obtain higher estehtic results compared to using abutments.



100% successful osseointegration achieved.



50% of participants could treat patients faster with matrix®.



10% improvement of bone levels, 72.5% stable crestal bone levels. 0% bone loss greater than 1mm.



OVERALL SUCCESS RATE

CONCLUSION:

2334 matrix® implants have been placed by the lead users since October 2020. A 99.7% success rate was achieved. Therefore, the study concludes that the **matrix**® implants can be considered safe.